Nimetazepam

Nimetazepam is a nitrazepam that is substituted at positions 1 by a methyl group. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia. Among its listed roles, it functions as a anticonvulsant, a sedative, a GABA modulator and an antispasmodic drug. It is a 1,4-benzodiazepinone and a C-nitro compound. Functionally, it is related to nitrazepam. Nimetazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance. Nimetazepam (marketed under brand name Erimin) is an intermediate-acting hypnotic drug that is a benzodiazepine derivative. It was first synthesized by a team at Hoffmann-La Roche in 1962. It is grouped under the following drug class(es): Benzodiazepines and Schedule IV controlled substances. Its therapeutic use is listed as sleeping drugs. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include 1-Methylnitrazepam, Erimin and Methylnitrazepam. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 4496.

CAS No 2011-67-8
Molecular Formula C16H13N3O3
Molecular Weight 295.29 g/mol
Synonyms 1-methyl-7-nitro-5-phenyl-3H-1,4-benzodiazepin-2-one

Frequently Asked Questions